Abstract
The last 20 years of the twentieth century witnessed a dramatic increase in research aimed at determining the mechanisms that regulate feeding behavior. Researchers, prompted by the alarming increase in the prevalence of obesity have identified many brain neuropeptides, especially in the hypothalamus that promote or inhibit food intake. How the complex interactions of these peptides leads to obesity has been clarified somewhat; unfortunately, this has not led to major advances in anti-obesity drug discovery. Continued effort during the first years of the new millennium has led to the discovery of new peptides mainly through inverse pharmacology techniques. In this article, we update information on obestatin, a closely related companion of ghrelin, on neuropeptide S, neuropeptide W, and others. These peptides use both classical and independent regulatory pathways to modulate feeding but often have additional biological activities. Strong arguments support a role in feeding regulation for some peptides. For others, this role remains controversial and further research is needed to clarify their exact effects.
Keywords: G-protein coupled receptor, Rfamide, neuromedins, 26Rfa, VGF, QRFP, hypothalamus, obesity
Central Nervous System Agents in Medicinal Chemistry
Title: Neuropeptides B, S and W, Obestatin/Ghrelin-Associated Peptide, and Others: Really New Feeding Regulatory Peptides?
Volume: 8 Issue: 1
Author(s): Bernard Beck, Carine Pourie and Jean-Louis Gueant
Affiliation:
Keywords: G-protein coupled receptor, Rfamide, neuromedins, 26Rfa, VGF, QRFP, hypothalamus, obesity
Abstract: The last 20 years of the twentieth century witnessed a dramatic increase in research aimed at determining the mechanisms that regulate feeding behavior. Researchers, prompted by the alarming increase in the prevalence of obesity have identified many brain neuropeptides, especially in the hypothalamus that promote or inhibit food intake. How the complex interactions of these peptides leads to obesity has been clarified somewhat; unfortunately, this has not led to major advances in anti-obesity drug discovery. Continued effort during the first years of the new millennium has led to the discovery of new peptides mainly through inverse pharmacology techniques. In this article, we update information on obestatin, a closely related companion of ghrelin, on neuropeptide S, neuropeptide W, and others. These peptides use both classical and independent regulatory pathways to modulate feeding but often have additional biological activities. Strong arguments support a role in feeding regulation for some peptides. For others, this role remains controversial and further research is needed to clarify their exact effects.
Export Options
About this article
Cite this article as:
Beck Bernard, Pourie Carine and Gueant Jean-Louis, Neuropeptides B, S and W, Obestatin/Ghrelin-Associated Peptide, and Others: Really New Feeding Regulatory Peptides?, Central Nervous System Agents in Medicinal Chemistry 2008; 8 (1) . https://dx.doi.org/10.2174/187152408783790640
DOI https://dx.doi.org/10.2174/187152408783790640 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Excess Exposure to Insulin Is the Primary Cause of Insulin Resistance and its Associated Atherosclerosis
Current Molecular Pharmacology Therapeutic Targets in Prostaglandin E2 Signaling for Neurologic Disease
Current Medicinal Chemistry Modulation of Interleukin-10 Production by Therapeutic Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Functional Chemical Groups that May Likely Become a Source for the Synthesis of Novel Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Immunoglobulin Free Light Chains in Immune Responses
Current Immunology Reviews (Discontinued) Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls
Current Psychiatry Reviews Gene Therapy for Pituitary Tumors
Current Gene Therapy Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Development of Prolactin Receptor Antagonists: Same Goal, Different Ways
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Neuroprotective Properties of Standardized Extracts of Hypericum perforatum on Rotenone Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Development of 11β -HSD1 Inhibitors for the Treatment of Type 2 Diabetes
Mini-Reviews in Medicinal Chemistry Melanocortins and their Receptors and Antagonists
Current Drug Targets Genetically Modified Mice as Tools to Understand the Neurobiological Substrates of Depression
Current Pharmaceutical Design Cerebrovascular Complications of Diabetes: Focus on Stroke
Endocrine, Metabolic & Immune Disorders - Drug Targets Review in Pharmacokinetic Models on Corticosteroids
Mini-Reviews in Medicinal Chemistry Non-Analgesic Effects of Opioids: Cardiovascular Effects of Opioids and their Receptor Systems
Current Pharmaceutical Design Donepezil May Reduce Insulin-Like Growth Factor-1 (IGF-1) Levels in Alzheimer’s disease
CNS & Neurological Disorders - Drug Targets The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Anaesthesia in Cancer Surgery: Can it Affect Cancer Survival?
Current Clinical Pharmacology